(Q43738821)

26 November 2017

title

Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients (English)

1 reference

26 November 2017

1 reference

1 reference

1 reference

1 reference

5

Schentag JJ

1 reference

26 November 2017

Smith PF

1

1 reference

26 November 2017

Ballow CH

series ordinal

2

1 reference

26 November 2017

Booker BM

series ordinal

3

1 reference

26 November 2017

Forrest A

series ordinal

4

1 reference

26 November 2017

publication date

1 August 2001

1 reference

26 November 2017

published in

Clinical Therapeutics

1 reference

26 November 2017

volume

23

1 reference

26 November 2017

issue

8

1 reference

26 November 2017

page(s)

1231-1244

1 reference

Effect of dose and schedule on cefoperazone pharmacodynamics in an in Vitro model of infection in a neutropenic host

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980103-X

7 January 2021

Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980103-X

7 January 2021

Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980103-X

7 January 2021

Role of pharmacokinetics in the outcome of infections

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980103-X

7 January 2021

Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980103-X

7 January 2021

Mathematical examination of dual individualization principles (II): The rate of bacterial eradication at the same area under the inhibitory curve is more rapid for ciprofloxacin than for cefmenoxime.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980103-X

7 January 2021

Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980103-X

7 January 2021

Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980103-X

7 January 2021

Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980103-X

7 January 2021

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980103-X

7 January 2021

Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980103-X

7 January 2021

Pharmacokinetics and extravascular penetration of aztreonam in patients with abdominal sepsis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980103-X

7 January 2021

Treatment with aztreonam or tobramycin in critical care patients with nosocomial gram-negative pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980103-X

7 January 2021

A Bayesian extension of the minimum AIC procedure of autoregressive model fitting

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980103-X

7 January 2021

Some suggestions for measuring predictive performance

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980103-X

7 January 2021

Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980103-X

7 January 2021

Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980103-X

7 January 2021

10.1016/S0149-2918(01)80103-X

Identifiers

DOI

1 reference

26 November 2017

1 reference